Article
Medicare groups in all but one state now cover the NMP22 BladderChek Test for both monitoring and diagnosis of bladder cancer, according to the test's manufacturer, Matritech.
Darolutamide is safe, efficacious in mHSPC regardless of patient age
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
STOPCAP: ARPIs benefit younger patients with mHSPC
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
UGN-101 associated with favorable long-term durability in low-grade UTUC
Mevrometostat/enzalutamide combo shows rPFS benefit in mCRPC